Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Naltrexone on Active Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All subjects must give written informed consent~* Male or female subjects, \> 18 years~* Patients must have endoscopic, histologic, or radiographic confirmed Crohn's Disease.~* Patients must have a Crohn's Disease Activity Index (CDAI) of at least 220 at Baseline~* Stable doses of medications for Crohn's disease over proceeding 4 weeks (for aminosalicylates and steroids: prednisone of 10mg or less daily and Entocort 3 mg/ day are allowed), and 12 weeks for azathioprine or 6-mercaptopurine.)~Exclusion Criteria:~* Subjects with ostomies or ileorectal anastomosis from prior surgical colectomy.~* Subjects who received infliximab (Remicade) within 8 weeks of study screening or humira for 4 weeks.~* Subjects requiring steroids either intravenously or prednisone \>10mg /day or Entocort \> 3 mg daily.~* Subjects with short-bowel syndrome.~* Abnormal liver enzymes at screening visit or known hepatitis or cirrhosis~* Hemoglobin less than 10.~* Subjects with cancer (other than skin cancer) in past 5 years.~* Women of childbearing potential unless surgically sterile or using adequate contraception (either IUD, oral or deport contraceptive, or barrier plus spermicide), and willing and able to continue contraception for 3 months after the completion of the study.~* Women who are pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo, Sugar pill (Type: PLACEBO_COMPARATOR): placebo for 3 months blinded then followed by an open-labelled study and all are treated with naltrexone 4.5 mg for 3 additional months
- Naltrexone-HCl (Type: ACTIVE_COMPARATOR): Subjects are treated in a blinded fashion for 3 months with naltrexone 4.5 mg po for active Crohn's disease followed an open-labelled study where naltrexone is given an additional 3 months at 4.5 mg po; hence the total treatment interval in this arm is 6 months. The response to the intervention administered is measured in the activity index and mucosal healing by colonoscopy.

Based on this trial design, predict the completion outcome and termination type (if applicable).